

Washington University School of Medicine

Digital Commons@Becker

---

Open Access Publications

---

2019

## Structural and functional evidence that lipoprotein LpqN supports cell envelope biogenesis in *Mycobacterium tuberculosis*

Geoff C. Melly

Haley Stokas

Jennifer L. Dunaj

Fong Fu Hsu

Malligarjunan Rajavel

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open\\_access\\_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

---

---

**Authors**

Geoff C. Melly, Haley Stokas, Jennifer L. Dunaj, Fong Fu Hsu, Malligarjunan Rajavel, Chih-Chia Su, Edward W. Yu, and Georgiana E. Purdy

---



# Structural and functional evidence that lipoprotein LpqN supports cell envelope biogenesis in *Mycobacterium tuberculosis*

Received for publication, April 6, 2019, and in revised form, August 27, 2019. Published, Papers in Press, August 30, 2019, DOI 10.1074/jbc.RA119.008781

Geoff C. Melly<sup>‡</sup>, Haley Stokas<sup>‡</sup>, Jennifer L. Dunaj<sup>‡</sup>, Fong Fu Hsu<sup>§</sup>, Malligarjuna Rajavel<sup>¶</sup>, Chih-Chia Su<sup>¶</sup>, Edward W. Yu<sup>¶</sup>, and Georgiana E. Purdy<sup>‡1</sup>

From the <sup>‡</sup>Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, Oregon 97239, the <sup>§</sup>Department of Internal Medicine, Mass Spectrometry Resource, Division of Endocrinology, Diabetes, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri 63110, and the <sup>¶</sup>Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106

Edited by Chris Whitfield

The mycobacterial cell envelope is crucial to host–pathogen interactions as a barrier against antibiotics and the host immune response. In addition, cell envelope lipids are mycobacterial virulence factors. Cell envelope lipid biosynthesis is the target of a number of frontline tuberculosis treatments and has been the focus of much research. However, the transport mechanisms by which these lipids reach the mycomembrane remain poorly understood. Many envelope lipids are exported from the cytoplasm to the periplasmic space via the mycobacterial membrane protein large (MmpL) family of proteins. In other bacteria, lipoproteins can contribute to outer membrane biogenesis through direct binding of substrates and/or protein–protein associations with extracytoplasmic biosynthetic enzymes. In this report, we investigate whether the lipoprotein LpqN plays a similar role in mycobacteria. Using a genetic two-hybrid approach, we demonstrate that LpqN interacts with periplasmic loop domains of the MmpL3 and MmpL11 transporters that export mycolic acid–containing cell envelope lipids. We observe that LpqN also interacts with secreted cell envelope biosynthetic enzymes such as Ag85A via pulldown assays. The X-ray crystal structures of LpqN and LpqN bound to dodecyl-trehalose suggest that LpqN directly binds trehalose monomycolate, the MmpL3 and Ag85A substrate. Finally, we observe altered lipid profiles of the  $\Delta$ *lpqN* mutant during biofilm maturation, pointing toward a possible physiological role for the protein. The results of this study suggest that LpqN may act as a membrane fusion protein, connecting MmpL transporters with periplasmic proteins, and provide general insight into the role of lipoproteins in *Mycobacterium tuberculosis* cell envelope biogenesis.

*Mycobacterium tuberculosis* (*Mtb*)<sup>2</sup> is the causative agent of the human disease tuberculosis (TB). TB is one of the most devastating human diseases, and it remains a major public health concern. In 2017, there were ~10 million new cases and 1.3 million deaths caused by TB (1). The cell envelope of *Mtb* is a waxy, lipid-rich structure that acts as a robust physical barrier to host antimicrobial defenses and antibiotics. This intrinsic resistance is largely conferred by mycolic acids, extremely long chain (C<sub>60–90</sub>)  $\alpha$ -alkyl- $\beta$ -hydroxy fatty acids that are major constituents of the mycobacterial cell envelope (2). Mycolic acids and their derivatives form an outer layer analogous to the outer membrane of Gram-negative bacteria, termed the mycomembrane. The mycomembrane consists of an inner leaflet of mycolylated arabinogalactan anchored to peptidoglycan (the mAGP complex) and an outer leaflet of predominantly mycolylated free lipids (3, 4). In addition to acting as a passive physical barrier, certain cell envelope components can directly interfere with host immune responses (5, 6). Therefore, the *Mtb* cell envelope plays a crucial role at the host–pathogen interface to promote bacterial survival.

The biogenesis of the mycobacterial cell envelope is complex and incompletely described. One class of proteins involved in transport of cell envelope components is the mycobacterial membrane protein large (MmpL) family. The MmpLs are polytopic membrane proteins that mediate transport of large hydrophobic substrates from the cytoplasm of the bacterium to the periplasmic space, where they are subsequently incorporated into the cell envelope (7–9). The MmpLs are considered members of the resistance–nodulation–cell division (RND) superfamily of membrane transporters that typically couple the proton motive force to export of their substrates (10, 11). A subset of MmpLs (MmpL1/2/4/5) are accompanied in the genome by genes encoding mycobacterial membrane protein

This work was supported by NIAID, National Institutes of Health Grants R21 AI113074 (to G. E. P.), R01 AI123148 (to G. E. P. and E. W. Y.), and by Grant T32 AI007472 (to G. C. M.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article contains Tables S1 and S2 and Figs. S1–S5.

The atomic coordinates and structure factors (codes 6E5D, 6E5F, and 6MNA) have been deposited in the Protein Data Bank (<http://www.pdb.org/>).

<sup>1</sup> To whom correspondence should be addressed. Tel.: 503-346-0767; E-mail: [purdyg@ohsu.edu](mailto:purdyg@ohsu.edu).

<sup>2</sup> The abbreviations used are: *Mtb*, *M. tuberculosis*; TB, tuberculosis; M-PFC, mycobacterial protein fragment complementation; RMSD, root-mean-square deviation; RND, resistance–nodulation–cell division; TMM, trehalose monomycolate; TDM, trehalose dimycolate; MFP, membrane fusion protein; PDIM, phthiocerol dimycolate; DHFR, dihydrofolate reductase; CFP, culture filtrate protein; 6LT, dodecyl trehalose; T6D, trehalose 6-decanoate; ADS, albumin dextrose salt; MAME, mycolic acid methyl ester; IPTG, isopropyl- $\beta$ -D-thiogalactopyranoside; SeMet, selenomethionyl.

## Characterization of *Mtb* LpqN

small (MmpS) proteins (12) that are predicted to contain one or two transmembrane segments and are likely involved in substrate transport by their cognate MmpL protein.

The substrates of a number of MmpL transporters have been identified. Of particular interest are those MmpL proteins that transport mycolic acid–containing lipids. Most importantly, MmpL3 (Rv0206c) transports trehalose monomycolate (TMM) into the periplasmic space (13). There, mycolic acid transfer catalyzed by members of the antigen 85 (Ag85) enzyme complex generates the free lipid trehalose dimycolate (TDM) and arabinogalactan-anchored mycolic acids, which together form the mycomembrane (13–15). MmpL3 is therefore an essential *Mtb* protein, because of the central role of mycolic acids in mycobacterial physiology (16, 17). Another important MmpL transporter is MmpL11 (Rv0202c), which we showed exports species-specific mycolic acid–containing storage lipids such as the mycolate wax ester and long-chain triacylglycerols in *Mtb* and meromycolyl diacylglycerol in *Mycobacterium smegmatis* (18, 19). These lipids are important for *Mtb* persistence, because MmpL11-deficient *Mtb* exhibit attenuated survival during *in vitro* and *in vivo* models of infection and in an *in vitro* model of dormancy (10, 19).

Many of the insights into MmpL transporter function have been gleaned from comparison with other protein members of the larger RND transporter superfamily. RND superfamily proteins are primarily associated with antibiotic resistance and stress response in Gram-negative bacteria (reviewed in Ref. 20). They typically function in concert with a membrane fusion protein (MFP) and an outer membrane factor to form a tripartite export apparatus that extrudes substrates through the periplasm directly to the extracellular environment (21–25). Although *Mtb* exhibits pseudo-Gram-negative membrane organization, it remains to be determined whether the MmpLs interact with periplasmic and outer membrane proteins to form a similar tripartite pump that would enable efficient translocation and proper localization of their substrates. Some secreted lipoproteins direct the proper localization of virulence-associated lipids within the cell envelope, suggesting that these proteins may be functioning as MFPs in *Mtb*. Notably, translocation of phthiocerol dimycolate (PDIM) to the mycomembrane depends on the lipoprotein LppX, presumably through direct binding of PDIM by LppX (26). Similarly, the lipoprotein LprG binds both the virulence-associated glycolipid lipoarabinomannan and triacylglycerides and is required for translocation of these substrates to the cell envelope (27). Furthermore, LprG interacts with the Ag85A mycolyltransferase, implicating this lipoprotein in the transmycolylation processes that generate the mycomembrane (28). The MmpS proteins are also candidate MFPs, given that MmpS4/5 interact with their cognate MmpL4/5 partners and are required for transport of their siderophore substrates (29). However, only a minority of MmpL transporters have cognate MmpS proteins (MmpS1/2/4/5), and MmpL-MmpS protein–protein interactions have not been demonstrated for MmpS1/2. This raises the possibility that there are unidentified *Mtb* proteins that function as quasi-MFPs to assist in delivering MmpL-transported lipids through the periplasm to their cell envelope destinations.

We sought to identify proteins that might function as MFPs with MmpL3 and MmpL11. Using genetic methods, we identified the secreted lipoprotein LpqN (Rv0583c) as a periplasmic interacting partner of both MmpL3 and MmpL11. Biochemical and genetic studies suggested that LpqN may also associate with members of the Ag85 enzyme complex and plays a role in cell envelope lipid changes during biofilm maturation. These results suggest that LpqN may function as an MFP of MmpL3/11. This model is supported by the crystal structures of apo- and lipid-bound LpqN reported herein.

## Results

### LpqN interacts with D2 loops of mycolate lipid transporters MmpL3 and MmpL11

MmpL3 and MmpL11 are structurally similar and categorized into the hydrophobe/amphiphile efflux 3 (HAE3) subfamily of the larger RND transporter superfamily (29, 30). They possess two periplasmic loop domains, termed D1 and D2, as well as a cytosolic C-terminal domain (31). The D1, D2, and C-terminal domains are therefore the most likely regions of interaction between MmpL11 and biosynthetic enzymes or other transport machinery. To identify periplasmic proteins that interact with MmpL11<sub>TB</sub>, we used the mycobacterial protein fragment complementation (M-PFC) system (32). In this two-hybrid system, the “bait” and “prey” are expressed independently as fusion proteins with two fragments of the murine dihydrofolate reductase (DHFR [F1,2] and DHFR [F3]). Functional reconstitution by two interacting mycobacterial proteins when expressed in *M. smegmatis* results in trimethoprim resistance. Integrative plasmids were constructed containing D1 and D2 domains in-frame with the DHFR [F3] fragment and then transformed into *M. smegmatis* to generate a bait strain. An H37Rv *Mtb* prey library of over 10<sup>6</sup> independent clones was generated in pUAB300. Clones encoding putative proteins that interact with MmpL11<sub>TB</sub> were obtained by transforming the library constructs into the *M. smegmatis* bait strain and selecting for trimethoprim resistance. Ultimately, no positive clones were identified using the D1 domain. Using the D2 construct, we isolated two independent clones that contained a DHFR [F1,2]–LpqN fusion. LpqN was the only positive clone identified using the MmpL11 D2 domain as bait. This suggests that LpqN (Rv0583c) interacts with the periplasmic D2 domain of MmpL11<sub>TB</sub>.

MmpL11 and MmpL3 are topologically similar conserved transporters of mycolic acid–containing lipids. Therefore, we theorized that LpqN might interact with the periplasmic domains of MmpL3 as well. To address this and validate our initial M-PFC screen, we assessed the interactions between the MmpL3 and MmpL11 periplasmic D1 and D2 loops with LpqN using a directly cloned (nonlibrary) LpqN prey construct, which contained the soluble domain of LpqN fused to DHFR [F1,2]. We found that the D2, but not the D1, loops of both MmpL3 and MmpL11 conferred trimethoprim resistance when co-expressed with LpqN (Table 1). These results suggest that LpqN interacts with the D2 periplasmic regions of both MmpL3 and MmpL11.

**Table 1**  
M-PFC assessed via trimethoprim minimal inhibitory concentrations of MmpL3/11<sub>TD</sub> D1 and D2 domain–LpqN interactions  
MIC, minimal inhibitory concentration.

| Insert in pUAB200 | Insert in pUAB300             | Trim MIC (μg/ml) |
|-------------------|-------------------------------|------------------|
| —                 | Rv2763 (dfr) positive control | >200             |
| —                 | LpqN                          | <6.25            |
| MmpL3 D1          | —                             | <6.25            |
| MmpL3 D1          | LpqN                          | <6.25            |
| MmpL11 D1         | —                             | <6.25            |
| MmpL11 D1         | LpqN                          | <6.25            |
| MmpL3 D2          | —                             | <6.25            |
| MmpL3 D2          | LpqN                          | 100              |
| MmpL11 D2         | —                             | <6.25            |
| MmpL11 D2         | LpqN                          | 50               |

To verify the interaction between LpqN and MmpL11 *in vivo*, we heterologously expressed affinity-tagged *Mtb* protein in *M. smegmatis*. Although both proteins were successfully expressed, we were unfortunately unable to co-purify LpqN with MmpL11 in the absence or presence of cross-linking (Fig. S1).

#### LpqN interacts with cell envelope lipid biosynthetic enzymes

We hypothesized that LpqN might act as an adaptor protein in the periplasm to facilitate interactions between MmpL proteins and periplasmic proteins. To identify secreted interacting partners of LpqN, we performed a pulldown purification of affinity-tagged LpqN incubated with *Mtb* culture filtrate proteins (CFPs) in the presence/absence of formaldehyde as a protein cross-linking reagent. Interacting proteins were subsequently identified via MS and categorized as weak or strong LpqN-interacting partners based on whether or not protein cross-linking was required for co-purification (Table 2). As a control, we analyzed the background binding of CFP to the metal affinity resin. Intriguingly, secreted cell envelope biosynthetic enzymes, such as the mycolyltransferase Ag85A and the mycocerosic acid synthase Mas, were enriched in the LpqN co-purified samples relative to background. Ag85B also copurified with LpqN, although to a lesser degree. Ag85 and Mas enzymes are responsible for the biosynthesis of the cell envelope lipids TDM and PDIM, respectively. These data suggest that LpqN interacts with periplasmic cell envelope biosynthetic enzymes.

The possible interaction between Ag85A and LpqN was interesting, given the key role that the Ag85 complex plays in the biogenesis of the mycobacterial cell envelope. Furthermore, the primary substrate of the Ag85 enzymes is TMM, which is exported by MmpL3. Attempts to demonstrate a direct interaction between LpqN and Ag85A using a heterologous dual-expression *M. smegmatis* co-immunopurification strategy were unsuccessful (Fig. S2). However, there is precedent for interactions between lipoproteins and members of the Ag85 complex, as evidenced by the recently reported LprG–Ag85A interaction (28). LprG (Rv1411c) binds phosphatidylinositol-containing glycolipids rather than mycolic acids (33). Nevertheless, LprG appears to contribute to mycolylation of cell wall analogues (28). We performed head-to-head M-PFC assays to determine whether the MmpL3 or MmpL11 D2 domains are capable of interacting with other LpqN family members (LpqT, Mtc28) or LprG. LpqT and Mtc28 also interact with the MmpL11 D2 domain, but not the MmpL3 D2 domain, via

M-PFC (Table S1). The structurally distinct LprG protein also interacted with the MmpL11, but not MmpL3, D2 domain via M-PFC. These results suggest the possibility that multiple lipoproteins act as adaptors for the MmpL transporters.

#### LpqN contributes to *Mtb* biofilm lipid composition

MmpL3 transports TMM, which is essential for replication, whereas MmpL11 transports cell envelope lipids that are important for biofilm formation. To investigate a possible role for LpqN in mycobacterial cell envelope biogenesis, we generated an *lpqN*-deletion mutant in H37Rv *Mtb* ( $\Delta$ *lpqN*) via allelic exchange (Fig. S3, A and B). There was not a growth defect in either 7H9 or Sauton's medium (Fig. S3, C and D). We then characterized *Mtb* WT,  $\Delta$ *lpqN*, and complemented strain cell envelope lipids from bacteria grown planktonically and in biofilms by TLC. We did not observe any differences in TMM and TDM levels between the WT, mutant, or complemented mutant (*Mtb*  $\Delta$ *lpqN::lpqN*) lipid profiles using the chloroform:methanol:ammonium hydroxide (80:20:2) solvent system (Fig. 1, A and B). We also analyzed the mycolic acid methyl esters of mAGP, which did not differ significantly between strains (Fig. 1C). Consistent with these results, we also did not see significant differences in the LC/MS profiles among the lipid extracts, in particular, of TMM and TDM (Figs. S4 and S5). This was not surprising because the  $\Delta$ *lpqN* mutant did not possess a growth defect.

Our analyses of *Mtb* biofilms over time indicate that the lipid profiles shift as the biofilm matures. Although there were no differences between WT and  $\Delta$ *lpqN* mutant lipids at 3 weeks (Fig. 1D), we noted the relative accumulation of an apolar lipid in the *lpqN* mutant samples that ran with a similar Rf to the wax ester standard in 4 weeks (Fig. 1E, asterisk). We speculated that the apolar lipid (Fig. 1E, asterisk) in the mutant was a wax ester. However, mass spectrometric analysis of the extract of this apolar TLC spot did not yield mass spectra that directly identified any known mycobacterial lipids. These results countered our assumption that the spot is wax ester and are consistent with HPLC/MS results that showed no difference in wax ester between WT and LpqN (Fig. S4E). The  $\Delta$ *lpqN* mutant biofilm also appeared to accumulate a less-apolar band that was similarly recalcitrant to identification (Fig. 1E, asterisks). Together, these biofilm lipid profiles suggest that LpqN may contribute to cell envelope lipid turnover or remodeling during biofilm development.

#### The LpqN crystal structure suggests that LpqN may directly bind lipids

To gain additional insight into LpqN function, the crystal structure of apo-LpqN was determined at a resolution of 1.65 Å using single anomalous dispersion (Table 3 and Fig. 2). Because LpqN might play a role in cell envelope biogenesis, we also determined structures of LpqN in complexes with dodecyl trehalose (6LT) and trehalose 6-decanoate (T6D) to resolutions of 1.37 and 1.74 Å, respectively. We resolved these two ligand-bound LpqN structures by using molecular replacement and utilizing the apo-LpqN structure as a search model (Table 3 and Fig. 2). Both 6LT and T6D are water-soluble compounds that are structurally similar to the insoluble lipid molecule TMM in that they contain a two-ring system of the trehalose moiety. Therefore, 6LT and T6D are ideal compounds to mimic TMM



## Characterization of *Mtb* LpqN

**Table 2**  
Interacting partners of LpqN in the culture filtrate

| Protein | CFP (background) <sup>a</sup>                    | CFP + LpqN (strong interactions) | Cross-linked (weak interactions) |        |
|---------|--|----------------------------------|----------------------------------|--------|
| Rv0583c | lipoprotein lpqN                                 | 54                               | 1862                             | 1774   |
| Rv2220  | glutamine synthetase glnA1                       | 15                               | 54                               | 121    |
| Rv3804c | fibronectin-binding protein antigen fbpA, Ag85A  | 18                               | 35                               | 100    |
| Rv1908c | catalase-peroxidase-peroxynitritase T katG       | 22                               | 46                               | 83     |
| Rv2780  | secreted L-alanine dehydrogenase ald             | 11                               | 32                               | 76     |
| Rv1475c | aconitate hydratase A acn                        | 3                                | 25                               | 60     |
| Rv1980c | immunogenic protein mpt64                        | 16                               | 21                               | 20     |
| Rv0350  | chaperone protein dnaK                           | 50                               | 60                               | 51     |
| Rv0896  | citrate synthase I gltA2                         | 3                                | 2                                | 57     |
| Rv006c  | isocitrate dehydrogenase icd2                    | 0                                | 0                                | 33     |
| Rv3248c | adenosylhomocysteinase sahH                      | 4                                | 4                                | 49     |
| Rv0440  | 60-kDa chaperonin groEL2                         | 9,818                            | 15.6                             | 18,947 |
| Rv1098c | fumarate hydratase fumC                          | 8                                | 8                                | 20     |
| Rv0211  | phosphoenolpyruvate carboxykinase pckA           | 4                                | 6                                | 26     |
| Rv2940c | mycocerosic acid synthase mas                    | 0                                | 3                                | 27     |
| Rv0363c | fructose-bisphosphate aldolase fba               | 2                                | 11                               | 23     |
| Rv2467  | aminopeptidase N pepN                            | 2                                | 5                                | 23     |
| Rv3418  | 10-kDa chaperonin groS                           | 7                                | 4                                | 22     |
| Rv2030c | uncharacterized protein                          | 1                                | 8                                | 21     |
| Rv0462  | dihydrolipoamide dehydrogenase lpd               | 0                                | 2                                | 20     |
| Rv1017c | ribose-phosphate pyrophosphokinase prsA          | 7                                | 13                               | 20     |
| Rv1074c | acetyl-CoA acetyltransferase fadA3               | 0                                | 3                                | 20     |
| Rv1886c | secreted fibronectin-binding protein fbpB, Ag85B | 0                                | 3                                | 19     |
| Rv1093  | serine hydroxymethyltransferase 1 glyA1          | 3                                | 6                                | 19     |
| Rv2244  | meromycolate extension acyl carrier protein acpM | 14                               | 13                               | 18     |
| Rv2031c | $\alpha$ -crystallin hspX                        | 1                                | 4                                | 17     |
| Rv0315  | probable $\beta$ -1,3-glucanase precursor        | 0                                | 0                                | 12     |
| Rv2146c | N-acetyltransferase eis                          | 0                                | 4                                | 11     |
| Rv1837c | malate synthase G glcB                           | 0                                | 0                                | 7      |
| Rv0934  | periplasmic phosphate-binding lipoprotein pstS1  | 0                                | 1                                | 6      |
| Rv0379  | protein transport protein secE2                  | 2                                | 0                                | 5      |
| Rv1860  | alanine and proline rich secreted protein apa    | 2                                | 0                                | 5      |
| Rv1392  | S-adenosylmethionine synthetase metK             | 0                                | 0                                | 5      |
| Rv0164  | conserved hypothetical protein TB18.5            | 0                                | 0                                | 4      |
| Rv1448c | transaldolase tal                                | 0                                | 0                                | 4      |
| Rv1449c | transketolase tkt                                | 0                                | 0                                | 4      |
| Rv3628  | inorganic pyrophosphatase ppa                    | 0                                | 0                                | 4      |

<sup>a</sup>Cell values are the summed spectral counts of identified peptides corresponding to the indicated protein, from three biological replicate experiments.


with respect to the interaction with LpqN. The crystals of apo-LpqN, LpqN-6LT, and LpqN-T6D took the space groups C121, I4, and I4, respectively. A single molecule of LpqN was found in the asymmetric unit of each crystal. The molecule of LpqN consists of three  $\alpha$ -helices and seven  $\beta$ -strands. These helices and strands are designated numerically from the N to C termini:  $\alpha$ 1 (61–68),  $\beta$ 1 (84–86),  $\beta$ 2 (104–108),  $\beta$ 3 (120–124),  $\alpha$ 2 (134–147),  $\beta$ 4 (170–176),  $\beta$ 5 (179–182),  $\beta$ 6 (184–192),  $\beta$ 7 (195–206), and  $\alpha$ 3 (210–222). Based on the orientation of apo-LpqN within the asymmetric unit, the dimensions of this protein can be measured to be 45 Å × 40 Å × 35 Å. Accordingly,  $\beta$ 4,  $\beta$ 5,  $\beta$ 6,  $\beta$ 7, and  $\alpha$ 3 are involved in forming a shallow cavity, presumably constituting a ligand binding site. The interior wall of this cavity consists mainly of hydrophobic and polar residues including Leu-87, Ile-121, Val-183, Ala-184, Leu-201, Ala-203, and Met-214.

Superimposition of the structures of apo-LpqN and LpqN-6LT results in an overall root-mean-square deviation (RMSD) of 0.8 Å, suggesting that these two structures are similar in conformation. However, detailed inspection indicates that the two structures are quite different. The main difference between the two conformations is the shift in location of  $\alpha$ 3 and the rearrangement of the secondary structures of several random loops located at the 6LT-binding site. These loops, including residues 93–96, 158–160, and 167–170, convert into  $\beta$  strands after binding 6LT. These changes result in a larger internal cavity for LpqN-6LT compared with that of apo-LpqN. In

addition, a specific deep binding pocket, which was not observed in apo-LpqN, was found in LpqN-6LT to coordinate with the binding of the carbon chain of the 6LT ligand. Because the secondary structure of LpqN-6LT is very different, we reassigned its structural features to facilitate the description of this ligand-bound protein. The secondary structure assignments of 6LT-bound LpqN from the N to C termini are:  $\alpha$ 1 (61–67),  $\beta$ 1 (93–96),  $\beta$ 2 (104–109),  $\alpha$ 2 (134–147),  $\beta$ 3 (158–160),  $\beta$ 4 (167–176),  $\beta$ 5 (179–185),  $\beta$ 6 (187–192),  $\beta$ 7 (195–206), and  $\alpha$ 3 (210–223).

In the structure of LpqN-6LT, the 6LT molecule is bound within the cavity surrounded by  $\beta$ 4,  $\beta$ 5,  $\beta$ 7, and  $\alpha$ 3. The dodecyl tail of 6LT is completely buried inside the LpqN protein, leaving its two sugar rings of the trehalose head group partially exposed to solvent. Within 6 Å of the dodecyl group of 6LT, 12 amino acids contact and secure the hydrocarbon tail (Fig. 3). Although the trehalose moiety of 6LT only partially contacts the LpqN protein, the binding of this two-ring head group is extensive. Ser-173 of LpqN forms a hydrogen bond with the trehalose head group to anchor this ligand. Gly-153 also donates its backbone oxygen to make another hydrogen bond with the trehalose moiety. Ser-154 and Gly-171 also participate in binding this head group. In addition, Gln-152 is 3.7 Å from the trehalose head group and interacts with the ligand via electrostatic interaction.

The structure of LpqN-T6D resembles that of LpqN-6LT. Superimposition of these two structures leads to an RMSD of



**Figure 1. LpqN contributes to biofilm lipid composition in late biofilm cultures.** *Mtb* was grown in either complete 7H9 medium or Sauton's medium lacking Tween for planktonic and biofilm cultures, respectively. *Mtb* cell envelope surface lipids were harvested by hexanes extraction from planktonic culture (A) or from biofilms harvested at 3 (B and D) or 4 (E) weeks and analyzed via TLC. mAGP was isolated from planktonic *Mtb* cell walls and MAMEs generated and visualized by TLC (C). The solvent systems used for TLC were 80:20:2, v/v/v,  $\text{CHCl}_3$ :MeOH: $\text{NH}_4\text{OH}$  (A and B); 99:5, v/v, hexanes:ethyl acetate (C); and 99:1, v/v, toluene:acetone (D and E). TDM, TMM, triacylglycerol (TAG), and wax ester (WE) standards are indicated (Sigma). All TLCs were developed by charring in 10% molybdophosphoric acid. In E, \* and \*\* indicate species that accumulate in the *lpqN* mutant.

0.1 Å, suggesting that these two structures are almost identical. Again, the main difference between the conformation of these two structures is the switch of local secondary structures from random loops to  $\beta$  strands. For example, residues 70–74, 84–86, 120–129, 160–162, 165–167, 185–187, and 225–227 are found to form flexible loops in the structure of LpqN–6LT. These residues are all incorporated into different  $\beta$  strands. Based on these structures, it appears that the LpqN protein is able to easily switch its secondary structures to accommodate for substrate binding. As a result, the LpqN–6LT forms three  $\alpha$ -helices and nine  $\beta$ -strands:  $\alpha$ 1 (61–67),  $\beta$ 1 (70–74),  $\beta$ 2 (84–

86),  $\beta$ 3 (93–96),  $\beta$ 4 (104–109),  $\beta$ 5 (120–129),  $\alpha$ 2 (134–147),  $\beta$ 6 (158–162),  $\beta$ 7 (165–176),  $\beta$ 8 (179–192),  $\beta$ 9 (195–206),  $\alpha$ 3 (210–223), and  $\beta$ 10 (225–227).

Like the binding of 6LT, the decanoate tail of T6D is completely buried in the binding cavity formed by LpqN. Within 6 Å of this hydrocarbon chain, at least eight amino acids are actively involved in anchoring the bound T6D. The trehalose head group of T6D is partially exposed to solvent and is surrounded by six amino acids. Ser-173 also participates by forming two hydrogen bonds with the sugar-ring system of T6D to secure the ligand (Fig. S4). The crystal structures of LpqN indeed sup-

## Characterization of *Mtb* LpqN

**Table 3**  
Data collection, phasing, and structural refinement statistics

|   | apo-LpqN (6E5D)        | LpqN-6LT (6E5F)        | LpqN-T6D (6MNA)        | SeMet-LpqN             |
|---|------------------------|------------------------|------------------------|------------------------|
| Wavelength (Å)                            | 0.9792                 | 0.9792                 | 0.9792                 | 0.9792                 |
| Resolution (Å)                            | 48.11–1.65 (1.71–1.65) | 56.57–1.37 (1.41–1.37) | 56.25–1.74 (1.85–1.74) | 48.59–2.20 (2.32–2.20) |
| Unit cell parameters                      |                        |                        |                        |                        |
| <i>a</i> , <i>b</i> , <i>c</i> (Å)        | 99.3, 55.5, 44.6       | 80.0, 80.0, 59.2       | 79.5, 79.5, 60.0       | 99.0, 56.4, 44.5       |
| $\alpha$ , $\beta$ , $\gamma$ (°)         | 90.0, 103.9, 90.0      | 90.0, 90.0, 90.0       | 90.0, 90.0, 90.0       | 90.0, 104.8, 90.0      |
| Space group                               | C121                   | I4                     | I4                     | C121                   |
| Total no. of reflections                  | 187,144                | 334,562                | 337,062                | 155,435                |
| Total no. of unique reflections           | 27,327                 | 39,223                 | 19,157                 | 12,099                 |
| Wilson B factor (Å <sup>2</sup> )         | 24.2                   | 20.73                  | 27.5                   | 42.6                   |
| Completeness (%)                          | 96.1 (87.3)            | 99.7 (98.0)            | 99.3 (98.5)            | 99.6 (98.2)            |
| Multiplicity                              | 6.9 (5.3)              | 8.4 (3.2)              | 17.6 (17.6)            | 12.8 (13.3)            |
| CC <sub>1/2</sub> (%)                     | 99.9 (95.6)            | 99.9 (64.5)            | 99.9 (64.3)            | 99.8 (98.2)            |
| <i>I</i> / $\sigma$ ( <i>I</i> )          | 19.0 (2.9)             | 18.2 (1.9)             | 11.1 (1.5)             | 15.3 (5.1)             |
| <b>Phasing</b>                            |                        |                        |                        |                        |
| No. of sites                              |                        |                        |                        | 2                      |
| Figure of merit                           |                        |                        |                        | 0.305                  |
| <b>Refinement</b>                         |                        |                        |                        |                        |
| <i>R</i> <sub>work</sub> (%) <sup>a</sup> | 18.57                  | 17.8                   | 18.45                  |                        |
| <i>R</i> <sub>free</sub> (%) <sup>b</sup> | 20.85                  | 20.35                  | 21.75                  |                        |
| No. of atoms                              |                        |                        |                        |                        |
| Protein                                   | 2654                   | 2661                   | 2559                   |                        |
| Water                                     | 140                    | 107                    | 101                    |                        |
| Ligand                                    |                        | 81                     | 74                     |                        |
| B factors (Å <sup>2</sup> )               |                        |                        |                        |                        |
| Protein                                   | 35.17                  | 30.96                  | 34.88                  |                        |
| Water                                     | 41.72                  | 37.98                  | 40.13                  |                        |
| Ligand                                    |                        | 70.05                  | 69.63                  |                        |
| RMSDs                                     |                        |                        |                        |                        |
| Bond lengths (Å)                          | 0.002                  | 0.004                  | 0.012                  |                        |
| Bond angle (°)                            | 0.545                  | 0.764                  | 1.242                  |                        |
| Ramachandran plot (%)                     |                        |                        |                        |                        |
| Favored regions                           | 96.84                  | 98.14                  | 100                    |                        |
| Allowed regions                           | 3.2                    | 1.8                    | 0                      |                        |
| Outliers                                  | 0                      | 0                      | 0                      |                        |

$$^a|R_{\text{work}} = \frac{\sum_{\text{hkl}} |F_{\text{obs}} - F_{\text{calc}}|}{\sum_{\text{hkl}} |F_{\text{obs}}|}$$

<sup>b</sup>*R*<sub>free</sub> was calculated as for *R*<sub>work</sub> but using 5% of the data that were excluded from the refinement calculation.

port the idea that this lipoprotein is capable of binding cell envelope lipids, such as TMM.

### Discussion


Using genetic methods, we demonstrated that LpqN interacts with the periplasmic D2 loop domains of the mycolate transporters MmpL3 and MmpL11. As such, LpqN may act as an MFP to facilitate substrate transport by MmpL3 and MmpL11. The outcome of this interaction is likely proper maturation of lipid substrates and/or the correct localization of these lipids within the cell envelope. We hypothesize that LpqN accomplishes these functions through direct binding of MmpL-transported lipids, as our structural data suggest.

Several observations suggest that there is substantial redundancy in this system. The cell envelope lipid profile of planktonic and 3-week biofilm-grown *Mtb*  $\Delta$ lpqN mutant did not differ from the WT, implying that the absence of LpqN does not affect the cell envelope lipid composition during these growth phases. Moreover, *Mtb*  $\Delta$ lpqN does not exhibit attenuated growth in planktonic culture (Fig. S1C). Because mycolic acid biosynthesis and MmpL3 are essential, we would expect that perturbing mycolic acid incorporation within the cell envelope would impact *Mtb* growth or viability. Given that lpqN-deficient *Mtb* grows at a normal rate and has a normal cell envelope lipid profile, LpqN is unlikely to be the sole facilitator of periplasmic mycolic acid transport in *Mtb*. In support of this, we note that the protein family to which LpqN belongs (PF10738) contains other secreted *Mtb* proteins such as the

lipoprotein LpqT (Rv1016c) and the secreted proline-rich Mtc28 (Rv0040c) (31).

Lipid binding may be a shared feature of the LpqN protein family. The published structure of Mtc28 exhibits structural homology to eukaryotic lipid-binding proteins such as CERT and STARD13, as assessed by the DALI server (34–37). Both LpqT and Mtc28, as well as the unrelated lipoprotein LprG (Rv1411c), interact with the MmpL11 D2 domain, but not the MmpL3 D2 domain, via M-PFC (Table S1). Whether LpqT and Mtc28 are capable of binding lipids is unknown, but LprG binds phosphatidylinositol-containing glycolipids and interacts with Ag85A (28, 33). Thus, there are presumably multiple interconnected and redundant pathways of cell envelope biogenesis operating in the periplasm that are mediated by lipoproteins and other secreted proteins. Some periplasmic lipid mediators, like LpqN, appear capable of interacting with both MmpL3 and MmpL11. Other potential mediators, like LpqT, Mtc28, and LprG, appear to preferentially interact with MmpL11. Although MmpL3 and MmpL11 both export mycolic acid-containing lipids, MmpL3 is essential and therefore more crucial to cell envelope physiology. Because lpqN-deficient *Mtb* is physiologically unimpaired, there are likely additional MmpL3-interacting periplasmic lipid mediators that remain to be identified. The recent characterization of the MmpL3-associated protein Ttfa in *M. smegmatis* supports the hypothesis that MmpLs function in concert with accessory proteins to transport their lipid substrates (38). LpqN and LpqN family proteins





**Figure 2. Structures of the *M. tuberculosis* LpqN protein.** *A*, representative section of electron density of apo-LpqN. The solvent-flattened electron density (50–1.65 Å) is contoured at 1.0  $\sigma$  and superimposed with the final refined model (green, carbon; red, oxygen; blue, nitrogen). *B*, ribbon diagram of a protomer of LpqN. The secondary structural elements of LpqN are colored green. *C*, surface representation of the electrostatic surface potentials of LpqN colored by charge (red, negative –15 kT/e; blue, positive +15 kT/e). *D*, representative section of electron density of LpqN–6LT. The solvent-flattened electron density (50–1.37 Å) is contoured at 1.0  $\sigma$  and superimposed with the final refined model (orange, carbon; red, oxygen; blue, nitrogen). *E*, ribbon diagram of a protomer of LpqN–6LT. The secondary structural elements of LpqN are colored orange. The bound 6LT is in cyan. *F*, surface representation of the electrostatic surface potentials of LpqN–6LT colored by charge (red, negative –15 kT/e; blue, positive +15 kT/e). A specific deep binding pocket, which was not observed in apo-LpqN, was found to create on the LpqN–6LT surface. *G*, representative section of electron density of LpqN–T6D. The solvent-flattened electron density (50–1.74 Å) is contoured at 1.0  $\sigma$  and superimposed with the final refined model (sky blue, carbon; red, oxygen; blue, nitrogen). *H*, ribbon diagram of a protomer of LpqN–T6D. The secondary structural elements of LpqN are colored sky blue. The bound T6D is in yellow. *I*, surface representation of the electrostatic surface potentials of LpqN–T6D colored by charge (red, negative –15 kT/e; blue, positive +15 kT/e). The bound T6D is in yellow. A specific deep binding pocket, which was not observed in apo-LpqN, was found to create on the LpqN–T6D surface.


are therefore likely redundant periplasmic mediators of lipid transport.

Our work raises a number of questions regarding the function of LpqN. An M-PFC screen performed in *M. smegmatis* initially identified LpqN as an interacting partner of MmpL11. We also used this system to show LpqN interaction with MmpL3. However, we were unable to demonstrate a direct biochemical interaction between LpqN and MmpL11 when heterologously co-expressed in *M. smegmatis*, suggesting a weak interaction (Fig. S1). We also cannot exclude the possibility that the LpqN–MmpL3/11 interaction is indirect and that some putative mycobacterial adaptor protein or molecule is required for LpqN to associate with these transporters. LpqN also appeared to preferentially interact with Ag85A when incubated with purified *Mtb* culture filtrate proteins. Similarly, we could

not successfully co-purify these two proteins when heterologously co-expressed in *M. smegmatis* (Fig. S2). Again, this may reflect an indirect interaction with a species specific adaptor protein. The observation that *Mtb*  $\Delta$ lpqN biofilms appear to mature differently than WT *Mtb* biofilms potentially suggests temporal modulation of LpqN function and is the focus of ongoing investigation.

Recent work demonstrated that LpqN contributes to *Mtb* virulence in a manner apart from its role in cell envelope biogenesis. LpqN appears to interact with the host ubiquitin ligase Cbl that down-regulates antibacterial immunity and potentiates *Mtb* growth during *ex vivo* macrophage infection (39). Although this capacity of LpqN to function as a virulence factor is ostensibly unrelated to its apparent role in cell envelope biogenesis, this finding underscores the critical impor-

## Characterization of Mtb LpqN



**Figure 3. The LpqN ligand-binding site.** *A*, the  $F_o - F_c$  simulated annealing electron density map of the bound 6LT within the LpqN protein. The bound 6LT is shown as a stick model (cyan, carbon; red, oxygen). The simulated annealing  $F_o - F_c$  electron density map is contoured at  $3.0 \sigma$  (gray mesh). *B*, the  $2F_o - F_c$  electron density map of the bound 6LT within the LpqN protein. The bound 6LT is shown as a stick model (cyan, carbon; red, oxygen). The  $2F_o - F_c$  electron density map is contoured at  $1.0 \sigma$  (blue mesh). *C*, schematic representation of the LpqN and 6LT interactions. Amino acid residues within  $3.5 \text{ \AA}$  from the bound 6LT are included. Dotted lines depict the hydrogen bonds. The hydrogen-bonded distances are also indicated in this figure. *D*, the  $F_o - F_c$  simulated annealing electron density map of the bound T6D within the LpqN protein. The bound T6D is shown as a stick model (yellow, carbon; red, oxygen). The simulated annealing  $F_o - F_c$  electron density map is contoured at  $3.0 \sigma$  (gray mesh). *E*, the  $2F_o - F_c$  electron density map of the bound T6D within the LpqN protein. The bound T6D is shown as a stick model (yellow, carbon; red, oxygen). The  $2F_o - F_c$  electron density map is contoured at  $1.0 \sigma$  (blue mesh). *F*, schematic representation of the LpqN and T6D interactions. Amino acid residues within  $3.5 \text{ \AA}$  from the bound T6D are included. Dotted lines depict the hydrogen bonds. The hydrogen-bonded distances are also indicated in this figure.



tance of the mycobacterial cell envelope and its components to pathogenesis.

## Experimental procedures

### Bacterial strains and growth conditions

The *Mtb* WT strain H37Rv was obtained from the ATCC. Mycobacterial strains were routinely maintained in Middlebrook 7H9 liquid medium (Difco) with 0.05% Tween 80 or on Middlebrook 7H10 agar (Difco), both supplemented with albumin dextrose salts (ADSs) containing 8.1 mg/ml NaCl, 50 mg/ml BSA, and 20 mg/ml dextrose. Glycerol was added to liquid 7H9 to a final concentration of 0.5%. Kanamycin (25  $\mu$ g/ml) and hygromycin (50  $\mu$ g/ml) were used to maintain bacterial selection when required.

The *Mtb*  $\Delta$ lpqN mutant was created via allelic exchange. Upstream and downstream regions of *lpqN* homology were amplified by PCR using  $\Delta$ lpqN 5'/3' Forward/Reverse primers (Table S2) and cloned to flank the hygromycin resistance gene in pYUB854-*rpsL* (40). The resulting linear hygromycin product flanked by regions of *lpqN* homology was amplified by PCR, purified, concentrated, and used to transform electrocompetent H37Rv/pJV53 (41). Transformants were selected on 7H10 agar containing ADS and hygromycin (75  $\mu$ g/ml). Individual colonies were transferred to 7H10 agar containing hygromycin (50  $\mu$ g/ml). Deletion of *lpqN* was confirmed via PCR using flanking primers. Loss of the pJV53 recombineering plasmid was accomplished through iterative culturing on 7H10 agar in the absence of kanamycin and confirmed by susceptibility to kanamycin (25  $\mu$ g/ml). For complementation, *lpqN* + ~1000-bp upstream sequence was amplified via PCR with *lpqN* -865/+1637 primers and cloned into the integrative vector pMV306 (42). The resulting complementation plasmid was transformed into the *Mtb*  $\Delta$ lpqN mutant and transformants selected on 7H10 agar containing ADS and kanamycin (25  $\mu$ g/ml) and confirmed via PCR (Fig. S1, A and B).

Mycobacterial biofilms were grown in Sauton's medium containing 0.5 g/liter  $K_2HPO_4$ , 0.5g/liter  $MgSO_4$ , 4.0 g/liter L-asparagine, 0.05 g/liter ferric ammonium citrate, 4.76% glycerol, and 1.0 mg/liter  $ZnSO_4$ , with a final pH of 7.0. *Mtb* biofilms were inoculated to  $A_{600} = 0.05$  in Sauton's medium and incubated at 37 °C in 5%  $CO_2$  in tightly sealed polystyrene bottles. At 2 weeks, the lids were loosened to permit gas exchange.

### Lipid isolation and analyses

*Mtb* lipids were harvested by collecting and centrifuging planktonic or biofilm cultures in 50-ml conical vials, washing once with PBS, and then moving to glass test tubes containing 3-mm glass beads. Surface lipids were extracted by shaking with hexanes (~5 ml) for 2 min, followed by pelleting (1000  $\times$  g/10 min). Supernatants were removed into fresh glass tubes and treated with HPLC-grade  $CHCl_3$ :MeOH (2:1, v/v) prior to removal from biosafety containment. For total lipid extraction, bacterial pellets were autoclaved prior to removal from biosafety containment, then extracted with ~5 ml of  $CHCl_3$ :MeOH (2:1, v/v) and 1 ml of HPLC-grade  $H_2O$  by shaking and bath sonication. The organic layer was separated by centrifugation (1000  $\times$  g/10 min), transferred to preweighed vial, and dried under inert  $N_2$  gas. mAGP was isolated as previously

described (43). Mycolic acid methyl esters (MAMEs) were obtained by incubating mAGP in 15% tetrabutylammonium hydroxide (overnight, 100 °C) followed by iodomethane (4 h, room temperature) and extraction with dichloromethane. Extracted lipids were resuspended in  $CHCl_3$  or dichloromethane (MAMEs) and loaded onto aluminum-backed silica plates (EMD Millipore) for TLC analysis. Solvent systems used were chloroform:methanol:ammonium hydroxide (80:20:2, v/v/v), hexanes:ethyl acetate (99:5, v/v, three developments), and toluene:acetone (99:1, v/v) (Fisher). Lipids were visualized via spraying with 12-molybdophosphoric acid (Alfa Aesar; 10%, w/v in EtOH) and charring. The extracted lipids were also subjected to LC/MS analysis using Agilent 6550A QTOF system in conjunction with Agilent 1290 HPLC. HPLC separation and MS data acquisition were performed as described previously (52).

### Mycobacterial protein fragment complementation assay

The M-PFC screen was previously described and relies on the reconstitution of two domains of the DHFR protein, which confers resistance to trimethoprim (32). The MmpL3 and MmpL11 D1 and D2 periplasmic domains were amplified by PCR, and the products were subcloned into pGEM-T Easy (Promega). Once confirmed by sequencing, the pUAB200 integrative plasmids were constructed such that the D1 and D2 domains were in-frame with the DHFR [F3] fragment. The pUAB200 was then transformed into *M. smegmatis* mc<sup>2</sup>155 generating bait strains. An H37Rv *Mtb* prey library of over 10<sup>6</sup> independent clones was generated in pUAB300. Briefly, H37Rv genomic DNA was partially digested with HpaI, and fragments between 0.5 and 2 kb were cloned into the ClaI site of pUAB300. Library DNA was generated by a MaxiPrep (Qiagen). To screen the library, electrocompetent bait strains were transformed with the *Mtb* library DNA and plated to Kan<sub>25</sub>/Hyg<sub>50</sub>/Trim<sub>50</sub> plates. Screens were considered successful if they resulted in 10<sup>6</sup> kan<sup>R</sup>hyg<sup>R</sup> transformants. Clones that grew on trimethoprim were screened by PCR to eliminate those that grew because of the presence of pUAB300 plasmids containing the *Mtb* *dfrA* (*Rv2763c*) gene. Sequencing of the prey *Mtb* genomic library plasmid identified the genes fused to DHFR [F1,2]. The MmpL11 D2-LpqN interaction was confirmed by direct cloning of LpqN lacking its signal sequence into pUAB300 to generate in frame fusions with the DHFR [F1,2] fragment. The MmpL D1 and D2-LpqN interactions were measured by determining the trimethoprim minimal inhibitory concentration. Similarly, LpqT, LprG, and Mtc28 were cloned without their signal sequences into pUAB300 to assess their interaction with MmpL3/11 D2 domains. A pUAB300 plasmid containing the *Mtb* *dfrA* (*Rv2763c*) gene was used as a positive control. Strains were serially diluted onto 7H11 agar containing 2-fold dilutions of trimethoprim from 6.25 to 200  $\mu$ g/ml.

### Protein purification

The *Escherichia coli* LpqN expression construct was created by amplifying *lpqN* lacking its signal sequence via PCR with primers *lpqN*.61/687 followed by subcloning into pGEM-T Easy. Upon sequence confirmation, the product was cloned into pET-15b (Novagen) in frame with an N-terminal six-histidine tag. This construct was transformed into *E. coli*

## Characterization of *Mtb* LpqN

BL21λDE3, and protein production was induced at  $A_{600} = \sim 0.5$  with 0.4 mM IPTG ( $\sim 1$  h/37 °C). Bacteria were harvested via centrifugation and lysed via sonication. Protein was affinity-purified over HisPur Cobalt Superflow agarose resin (Thermo) and confirmed by Western blotting analysis.

### LpqN–CFP pulldowns

Recombinantly expressed LpqN and CFPs (BEI Resources, NR-14825, lot no. 610560541) (500 μg each) were incubated overnight at 4 °C in buffer A (300 mM NaCl, 50 mM NaPO<sub>4</sub>). Cross-linking was performed using 1% formaldehyde for 30 min at room temperature, followed by quenching with 225 mM glycine for 5 min. Cross-linked samples were buffer-exchanged back into buffer A prior to LpqN purification on HisPur Cobalt Superflow agarose resin (Thermo). LpqN from the non-cross-linked sample was similarly purified. Background CFP binding was assessed by flowing 500 μg of CFP alone over the cobalt resin. All resin-immobilized samples were washed (twice in buffer A and once in buffer A + 10 mM imidazole) and eluted in buffer A + 200 mM imidazole. LpqN-interacting proteins and CFP background were identified by MS at the Oregon Health & Science University Proteomics Shared Resource.

### Protein mass spectrometry

0.5 ml of each eluate was concentrated and buffer-exchanged with Amicon Ultra 3-kDa molecular mass cutoff filter. Samples were solubilized in 0.05% ProteaseMAX, reduced with DTT, alkylated with iodoacetamide, digested with trypsin overnight, and dried. Each sample was dissolved in 20 μl of 5% formic acid, and 20 μl/sample was injected into Orbitrap Fusion. Sample digests were loaded onto an Acclaim PepMap 0.1 × 20 mm NanoViper C18 peptide trap (Thermo Scientific) for 5 min at a 5 μl/min flow rate in a 2% acetonitrile, 0.1% formic acid mobile phase, and peptides separated using a PepMap RSLC C18, 2-μm particle, 75-μm × 25-cm EasySpray column (Thermo Scientific) using a 7.5–30% acetonitrile gradient over 60 min in mobile phase containing 0.1% formic acid and a 300 nl/min flow rate using a Dionex NCS-3500RS UltiMate RSLC nano UPLC system. Tandem MS data were collected using an Orbitrap Fusion Tribrid mass spectrometer configured with an EasySpray NanoSource (Thermo Scientific). Survey scans were performed in the Orbitrap mass analyzer at 120,000 resolution, and data-dependent MS2 scans were performed in the linear ion trap using higher-energy collisional dissociation following isolation with the instrument's quadrupole. Comet (version 2015.01, revision 1) was used to search MS2 Spectra against an April 2017 version of the uniprot\_Mycobacterium.tuberculosis\_h37rv\_both.fasta (8352 entries) FASTA protein database, with concatenated sequence-reversed entries to estimate error thresholds and 179 common contaminant sequences and their reversed forms (44). The database processing was performed with Python scripts available at [https://github.com/pwilmart/fasta\\_utilities.git](https://github.com/pwilmart/fasta_utilities.git).<sup>3</sup> Comet searches for all samples were performed with trypsin enzyme specificity. The average parent ion mass tolerance was 2.5 Da. Monoisotopic fragment ion mass tolerance was 1.005 Da. A

static modification of +57.02146 Da was added to all cysteine residues. A variable modification of +15.99491 Da on methionine residues was also allowed.

### LpqN expression and purification for crystallization studies

Briefly, the LpqN protein containing a His<sub>6</sub> tag at the C terminus was overproduced in *E. coli* BL21(DE3) cells possessing pET15bΩLpqN. The cells were grown in 2 liters of LB medium with 100 μg/ml ampicillin at 37 °C. When the  $A_{600}$  reached 0.5, the culture was treated with 0.2 mM IPTG to induce LpqN expression, and the cells were harvested within 3 h. The collected bacterial cells were suspended in 100 ml of ice-cold buffer containing 20 mM Na-HEPES (pH 7.2), 200 mM NaCl, 10 mM MgCl<sub>2</sub>, and 0.2 mg DNase I (Sigma–Aldrich). The cells were then lysed with a French pressure cell. Cell debris was removed by centrifugation for 45 min at 4 °C and 20,000 rpm. The crude lysate was filtered through a 0.2-μm membrane and was loaded onto a 5-ml Hi-Trap Ni<sup>2+</sup>-chelating column (GE Healthcare Biosciences, Pittsburgh, PA) pre-equilibrated with 20 mM Na-HEPES (pH 7.2) and 200 mM NaCl. To remove unbound proteins and impurities, the column was first washed with six column volumes of buffer containing 50 mM imidazole, 250 mM NaCl, and 20 mM Na-HEPES (pH 7.2). The LpqN protein was then eluted with four column volumes of buffer containing 300 mM imidazole, 250 mM NaCl, and 20 mM Na-HEPES (pH 7.2). The purity of the protein was judged using 12.5% SDS-PAGE stained with Coomassie Brilliant Blue. The purified protein was extensively dialyzed against buffer containing 20 mM Na-HEPES (pH 7.5), and concentrated to 15 mg/ml.

For the His<sub>6</sub> selenomethionyl (SeMet)-substituted LpqN protein expression, a 1-ml LB broth overnight culture containing *E. coli* BL21(DE3)/pET15bΩLpqN cells was transferred into 20 ml of LB broth containing 100 μg/ml ampicillin and grown at 37 °C. When the  $A_{600}$  value reached 1.2, the cells were harvested by centrifugation at 3000 × g/min for 10 min and then washed two times with 10 ml of M9 minimal salt solution. The cells were resuspended in 20 ml of M9 medium and then transferred into a 2-liter prewarmed M9 solution containing 100 μg/ml ampicillin. The cell culture was incubated at 37 °C with shaking. When the  $A_{600}$  reached 0.4, 100 mg/liter of lysine, phenylalanine, and threonine; 50 mg/liter isoleucine, leucine, and valine; and 60 mg/liter of L-selenomethionine were added. The culture was continued to incubate at 37 °C with shaking for 15 min. Protein expression was induced with 0.2 mM IPTG, and the cells were harvested within 3 h after induction. The procedures for purifying His<sub>6</sub> SeMet–LpqN were identical to those of native LpqN.

### Crystallization of LpqN

All crystals of the His<sub>6</sub> LpqN protein were obtained using hanging-drop vapor diffusion. The LpqN crystals were grown at room temperature in 24-well plates with the following procedures. A 20-μl protein solution containing 15 mg/ml LpqN protein in 20 mM Na-HEPES (pH 7.5) was mixed with a 2 μl of reservoir solution containing 0.1 M sodium citrate (pH 6.0) and 1.9 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. The resultant mixture was equilibrated against 500 μl of the reservoir solution. Crystals grew to a full size in the drops within 2 weeks. Cryoprotection was achieved by raising the glycerol concentration stepwise to 25% with a 5% increment in each step.

<sup>3</sup> Please note that the JBC is not responsible for the long-term archiving and maintenance of this site or any other third party hosted site.



Crystals of SeMet–LpqN were prepared using similar procedures. The reservoir solution for crystallizing SeMet–LpqN is the same as that for native LpqN. These SeMet crystals grew to a full size in the drops within 2 weeks. Cryoprotection was achieved by raising the glycerol concentration stepwise to 25% with a 5% increment in each step.

The LpqN–6LT or LpqN–T6D crystals were prepared by incubating the purified LpqN protein (15 mg/ml) with 0.1% 6LT or 0.1% T6D for 2 h at 4 °C before crystallization. Crystals of LpqN–6LT and LpqN–T6D were then prepared using similar procedures as above. Their crystallization conditions are identical to each other. The reservoir solution for these complex crystals is the same as that for apo-LpqN (0.1 M sodium citrate, pH 6.0, and 1.9 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>). Both crystals of LpqN–6LT and LpqN–T6D grew to a full size in the drops within 2 weeks. Cryoprotection was achieved by raising the glycerol concentration stepwise to 25% with a 5% increment in each step.

#### Data collection, structural determination, and refinement

All diffraction data were collected at 100 K at Beamline 24ID-C located at the Advanced Photon Source, using a Pilatus 6M detector (Dectris Ltd.). Diffraction data were processed using DENZO and scaled using SCALEPACK (45). Crystals of LpqN, LpqN–6LT, LpqN–T6D, and SeMet–LpqN belong to space groups C121, I4, I4, and C121, respectively (Table 3).

The LpqN protein contains two methionines (excluding the N-terminal methionine). Within the asymmetric unit of SeMet–LpqN, these two selenium sites were identified using SHELXC and SHELXD (46) as implemented in the HKL2MAP package (47). Single anomalous dispersion was employed to obtain experimental phases using the program Autosol (48) in PHENIX (49). The resulting phases were then subjected to density modification and NCS averaging using the program PARROT (50) using the native structure factor amplitudes. The SeMet sites were also used to trace the molecule by anomalous difference Fourier maps, where we could ascertain the proper registry of SeMet residues. The initial model of LpqN was constructed manually using program Coot (51). Then the model was refined using PHENIX, leaving 5% of reflections in the Free-R set. Iterations of refinement were performed using PHENIX. Model buildings were done using Coot, which led to the current model (Table 3).

The crystal structures of LpqN–6LT and LpqN–T6D were determined by molecular replacement, utilizing the final structure of LpqN as a search model. The procedures for structural refinement and model building were the same as those of LpqN (Table 3).

#### LpqN–MmpL11/Ag85A interaction

HA-tagged LpqN was amplified by PCR using lpqN –570.F/+HA.R primers and the resulting product cloned into the pOLYG plasmid to generate pOLYG lpqN HA where LpqN is expressed from its native promoter. MmpL11 was amplified using mmpL11 TAP.F/R primers and ligated in-frame with the tandem affinity-tagged (TAP; His<sub>6</sub> and FLAG tag) tag into pOLYG-TAP plasmid to generate pOLYG mmpL11-TAP plasmid. MmpL11 expression in the pOLYG mmpL11 TAP is

driven by its native promoter. The lpqN-HA fragment was ligated into the pOLYGmmpL11–TAP plasmid to generate the pOLYGlpqN–HA/mmpL11–TAP co-expression plasmid. HIS-tagged Ag85A was amplified using Ag85A.F/R primers and ligated into the pOLYG plasmid via NEBuilder (New England Biolabs) to generate pOLYGag85A-HIS. The lpqN HA fragment was ligated into the pOLYGag85a-HIS plasmid to generate the pOLYGlpqN-HA/ag85A-HIS co-expression plasmid, as above. To test the LpqN/MmpL11 interaction, *M. smegmatis* mc<sup>2</sup>155 was transformed with either pOLYGlpqN-HA or pOLYGlpqN-HA/mmpL11-TAP, and grown in 7H9 liquid medium, as above. Protein cross-linking was induced by adding formaldehyde to a final concentration of 1% for 30 min at room temperature. All samples were quenched with 2.5 M glycine, washed with 1× PBS, and lysed in urea lysis buffer (8 M urea, 300 mM NaCl, 0.5% Nonidet P-40, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 50 mM Tris, Roche Complete protease inhibitor, pH 7.0) via sonication. The lysates were incubated on buffer-equilibrated HisPur Cobalt Superflow agarose resin (Thermo Scientific), washed extensively, and eluted in urea lysis buffer adjusted to 300 mM imidazole. Resin flow through and elutions were separated via SDS-PAGE (10%) and analyzed by Western blotting (1:2500 mouse monoclonal α-FLAG/α-HA; Thermo Scientific). To test the LpqN/Ag85A interaction, *M. smegmatis* was transformed with pOLYGag85a-His or pOLYGlpqN-HA/ag85A-HIS and cross-linked as above. Washed cell pellets were lysed in 1× PBS + Roche Complete protease inhibitor via sonication and incubated on Pierce HA epitope tag antibody agarose conjugate (Thermo Scientific). Resin-bound proteins were extensively washed in lysis buffer, eluted in 50 mM NaOH, and immediately quenched with 1.0 M Tris, pH 8.5. Lysates, resin flow-through, and elutions were separated via SDS-PAGE (15%) and analyzed by Western blotting (1:1000 rabbit polyclonal α-HIS/α-HA; Thermo Scientific).

**Author contributions**—G. C. M. conceptualization; G. C. M., H. S., J. L. D., F. F. H., M. R., C.-C. S., E. W. Y., and G. E. P. investigation; G. C. M. writing-original draft; G. C. M., F. F. H., E. W. Y., and G. E. P. writing-review and editing; F. F. H., M. R., C.-C. S., E. W. Y., and G. E. P. formal analysis; E. W. Y. and G. E. P. supervision; G. E. P. funding acquisition; G. E. P. project administration.

**Acknowledgments**—Protein mass spectrometric analysis was performed by the Oregon Health & Science University Proteomics Shared Resource with partial support from National Institutes of Health Core Grants P30EY010572, P30CA069533, and S10OD012246. Lipid mass spectrometric analysis was performed by the Washington University Biomedical Mass Spectrometry Research Resource, which is supported by National Institutes of Health Grants P41-GM103422, P60-DK-20579, and P30-DK56341. This work is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P30 GM124165). The Pilatus 6M detector on 24-ID-C beam line is funded by a NIH-ORIP HEI grant (S10 RR029205). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

## References

1. *Global Tuberculosis Report* (2018) World Health Organization, Geneva, Switzerland
2. Barry, C. E., 3rd, Lee, R. E., Mdluli, K., Sampson, A. E., Schroeder, B. G., Slayden, R. A., and Yuan, Y. (1998) Mycolic acids: structure, biosynthesis and physiological functions. *Prog. Lipid Res.* **37**, 143–179 [CrossRef Medline](#)
3. Chiaradia, L., Lefebvre, C., Parra, J., Marcoux, J., Burlet-Schiltz, O., Etienne, G., Tropis, M., and Daffé, M. (2017) Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane. *Sci. Rep.* **7**, 12807 [CrossRef Medline](#)
4. Marrakchi, H., Lanéelle, M.-A., and Daffé, M. (2014) Mycolic acids: structures, biosynthesis, and beyond. *Chem. Biol.* **21**, 67–85 [CrossRef Medline](#)
5. Blanc, L., Gilleron, M., Prandi, J., Song, O.-R., Jang, M.-S., Gicquel, B., Drocourt, D., Neyrolles, O., Brodin, P., Tiraby, G., Vercellone, A., and Nigou, J. (2017) *Mycobacterium tuberculosis* inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. *Proc. Natl. Acad. Sci. U.S.A.* **114**, 11205–11210 [CrossRef Medline](#)
6. Cambier, C. J., Takaki, K. K., Larson, R. P., Hernandez, R. E., Tobin, D. M., Urdahl, K. B., Cosma, C. L., and Ramakrishnan, L. (2014) Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. *Nature* **505**, 218–222 [CrossRef Medline](#)
7. Chalut, C. (2016) MmpL transporter-mediated export of cell-wall associated lipids and siderophores in mycobacteria. *Tuberculosis* **100**, 32–45 [CrossRef Medline](#)
8. Viljoen, A., Dubois, V., Girard-Misguich, F., Blaise, M., Herrmann, J.-L., and Kremer, L. (2017) The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments. *Mol. Microbiol.* **104**, 889–904 [CrossRef Medline](#)
9. Melly, G., and Purdy, G. E. (2019) MmpL proteins in physiology and pathogenesis of *M. tuberculosis*. *Microorganisms* **7**, E70 [CrossRef Medline](#)
10. Domenech, P., Reed, M. B., and Barry, C. E., 3rd (2005) Contribution of the *Mycobacterium tuberculosis* MmpL protein family to virulence and drug resistance. *Infect. Immun.* **73**, 3492–3501 [CrossRef Medline](#)
11. Ruggerone, P., Murakami, S., Pos, K. M., and Vargiu, A. V. (2013) RND efflux pumps: structural information translated into function and inhibition mechanisms. *Curr. Top. Med. Chem.* **13**, 3079–3100 [CrossRef Medline](#)
12. Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., 3rd, Tekaia, F., Badcock, K., Basham, D., Brown, D., Chillingworth, T., et al. (1998) Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* **393**, 537–544 [CrossRef Medline](#)
13. Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E., Korduláková, J., Chavadi, S. S., Morisseau, C., Lenaerts, A. J., Lee, R. E., McNeil, M. R., and Jackson, M. (2012) Inhibition of mycolic acid transport across the *Mycobacterium tuberculosis* plasma membrane. *Nat. Chem. Biol.* **8**, 334–341 [CrossRef Medline](#)
14. Backus, K. M., Dolan, M. A., Barry, C. S., Joe, M., McPhie, P., Boshoff, H. I., Lowary, T. L., Davis, B. G., and Barry, C. E., 3rd (2014) The three *Mycobacterium tuberculosis* antigen 85 isoforms have unique substrates and activities determined by non-active site regions. *J. Biol. Chem.* **289**, 25041–25053 [CrossRef Medline](#)
15. Belisle, J. T., Vissa, V. D., Sievert, T., Takayama, K., Brennan, P. J., and Besra, G. S. (1997) Role of the major antigen of *Mycobacterium tuberculosis* in cell wall biogenesis. *Science* **276**, 1420–1422 [CrossRef Medline](#)
16. Degiacomi, G., Benjak, A., Madacki, J., Boldrin, F., Provvedi, R., Palù, G., Kordulakova, J., Cole, S. T., and Manganelli, R. (2017) Essentiality of mmpL3 and impact of its silencing on *Mycobacterium tuberculosis* gene expression. *Sci. Rep.* **7**, 43495 [CrossRef Medline](#)
17. Li, W., Obregón-Henao, A., Wallach, J. B., North, E. J., Lee, R. E., Gonzalez-Juarrero, M., Schnappinger, D., and Jackson, M. (2016) Therapeutic potential of the *Mycobacterium tuberculosis* mycolic acid transporter, MmpL3. *Antimicrob. Agents Chemother.* **60**, 5198–5207 [CrossRef Medline](#)
18. Pacheco, S. A., Hsu, F. F., Powers, K. M., and Purdy, G. E. (2013) MmpL11 protein transports mycolic acid-containing lipids to the mycobacterial cell wall and contributes to biofilm formation in *Mycobacterium smegmatis*. *J. Biol. Chem.* **288**, 24213–24222 [CrossRef Medline](#)
19. Wright, C. C., Hsu, F. F., Arnett, E., Dunaj, J. L., Davidson, P. M., Pacheco, S. A., Harriff, M. J., Lewinsohn, D. M., Schlesinger, L. S., and Purdy, G. E. (2017) The *Mycobacterium tuberculosis* MmpL11 cell wall lipid transporter is important for biofilm formation, intracellular growth and non-replicating persistence. *Infect. Immun.* **10.1128/IAI.00131-17**
20. Delmar, J. A., Su, C. C., and Yu, E. W. (2014) Bacterial multidrug efflux transporters. *Annu. Rev. Biophys.* **43**, 93–117 [CrossRef Medline](#)
21. Okusu, H., Ma, D., and Nikaido, H. (1996) AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of *Escherichia coli* multiple-antibiotic-resistance (Mar) mutants. *J. Bacteriol.* **178**, 306–308 [CrossRef Medline](#)
22. Ma, D., Cook, D. N., Alberti, M., Pon, N. G., Nikaido, H., and Hearst, J. E. (1993) Molecular cloning and characterization of *acrA* and *acrE* genes of *Escherichia coli*. *J. Bacteriol.* **175**, 6299–6313 [CrossRef Medline](#)
23. Dinh, T., Paulsen, I. T., and Saier, M. H. (1994) A family of extracytoplasmic proteins that allow transport of large molecules across the outer membranes of gram-negative bacteria. *J. Bacteriol.* **176**, 3825–3831 [CrossRef Medline](#)
24. Paulsen, I. T., Park, J. H., Choi, P. S., and Saier, M. H. (1997) A family of Gram-negative bacterial outer membrane factors that function in the export of proteins, carbohydrates, drugs and heavy metals from Gram-negative bacteria. *FEMS Microbiol. Lett.* **156**, 1–8 [CrossRef Medline](#)
25. Zgurskaya, H. I., and Nikaido, H. (1999) Bypassing the periplasm: reconstitution of the AcrAB multidrug efflux pump of *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 7190–7195 [CrossRef Medline](#)
26. Sulzenbacher, G., Canaan, S., Bordat, Y., Neyrolles, O., Stadthagen, G., Roig-Zamboni, V., Raugier, J., Maurin, D., Laval, F., Daffé, M., Cambillau, C., Gicquel, B., Bourne, Y., and Jackson, M. (2006) LppX is a lipoprotein required for the translocation of phthiocerol dimycocerosates to the surface of *Mycobacterium tuberculosis*. *EMBO J.* **25**, 1436–1444 [CrossRef Medline](#)
27. Martinot, A. J., Farrow, M., Bai, L., Layre, E., Cheng, T.-Y., Tsai, J. H., Iqbal, J., Annand, J. W., Sullivan, Z. A., Hussain, M. M., Sacchettini, J., Moody, D. B., Seeliger, J. C., and Rubin, E. J. (2016) Mycobacterial metabolic syndrome: LprG and Rv1410 regulate triacylglyceride levels, growth rate and virulence in *Mycobacterium tuberculosis*. *PLoS Pathog.* **12**, e1005351-26 [CrossRef Medline](#)
28. Touchette, M. H., Van Vlack, E. R., Bai, L., Kim, J., Cognetta, A. B., 3rd, Previti, M. L., Backus, K. M., Martin, D. W., Cravatt, B. F., and Seeliger, J. C. (2017) A screen for protein-protein interactions in live mycobacteria reveals a functional link between the virulence-associated lipid transporter LprG and the mycolyltransferase antigen 85A. *ACS Infect. Dis.* **3**, 336–348 [CrossRef Medline](#)
29. Sandhu, P., and Akhter, Y. (2017) Siderophore transport by MmpL5-MmpS5 protein complex in *Mycobacterium tuberculosis*. *J. Inorg. Biochem.* **170**, 75–84 [CrossRef Medline](#)
30. Tseng, T. T., Gratwick, K. S., Kollman, J., Park, D., Nies, D. H., Goffeau, A., and Saier, M. H. (1999) The RND permease superfamily: an ancient, ubiquitous and diverse family that includes human disease and development proteins. *J. Mol. Microbiol. Biotechnol.* **1**, 107–125 [Medline](#)
31. Chim, N., Torres, R., Liu, Y., Capri, J., Batot, G., Whitelegge, J. P., and Goulding, C. W. (2015) The structure and interactions of periplasmic domains of crucial MmpL membrane proteins from *Mycobacterium tuberculosis*. *Chem. Biol.* **22**, 1098–1107 [CrossRef Medline](#)
32. Singh, A., Mai, D., Kumar, A., and Steyn, A. J. (2006) Dissecting virulence pathways of *Mycobacterium tuberculosis* through protein-protein association. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 11346–11351 [CrossRef Medline](#)
33. Drage, M. G., Tsai, H.-C., Pecora, N. D., Cheng, T.-Y., Arida, A. R., Shukla, S., Rojas, R. E., Seshadri, C., Moody, D. B., Boom, W. H., Sacchettini, J. C., and Harding, C. V. (2010) *Mycobacterium tuberculosis* lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. *Nature Struct. Mol. Biol.* **17**, 1088–1095 [CrossRef](#)
34. Holm, L., and Rosenström, P. (2010) Dali server: conservation mapping in 3D. *Nucleic Acids Res.* **38**, W545–W549 [CrossRef Medline](#)

35. Kundu, P., Biswas, R., Mukherjee, S., Reinhard, L., Dutta, A., Mueller-Dieckmann, J., Weiss, M. S., Pal, N. K., and Das, A. K. (2016) Structure-based epitope mapping of *Mycobacterium tuberculosis* secretory antigen MTC28. *J. Biol. Chem.* **291**, 13943–13954 [CrossRef Medline](#)
36. Kudo, N., Kumagai, K., Tomishige, N., Yamaji, T., Wakatsuki, S., Nishijima, M., Hanada, K., and Kato, R. (2008) Structural basis for specific lipid recognition by CERT responsible for nonvesicular trafficking of ceramide. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 488–493 [CrossRef Medline](#)
37. Thorsell, A.-G., Lee, W. H., Persson, C., Siponen, M. I., Nilsson, M., Busam, R. D., Kotenyova, T., Schüller, H., and Lehtiö, L. (2011) Comparative structural analysis of lipid binding START domains. *PLoS One* **6**, e19521 [CrossRef Medline](#)
38. Fay, A., Czudnochowski, N., Rock, J. M., Johnson, J. R., Krogan, N. J., Rosenberg, O., and Glickman, M. S. (2019) Two accessory proteins govern MmpL3 mycolic acid transport in mycobacteria. *mBio*. **10**, e00850-19 [Medline](#)
39. Penn, B. H., Netter, Z., Johnson, J. R., Von Dollen, J., Jang, G. M., Johnson, T., Ohol, Y. M., Maher, C., Bell, S. L., Geiger, K., Golovkine, G., Du, X., Choi, A., Parry, T., Mohapatra, B. C., et al. (2018) An Mtb-human protein–protein interaction map identifies a switch between host antiviral and antibacterial responses. *Mol. Cell* **71**, 637–648.e5 [CrossRef Medline](#)
40. Bardarov, S., Bardarov, S., Jr, Pavelka, M. S., Jr, Sambandamurthy, V., Larsen, M., Tufariello, J., Chan, J., Hatfull, G., and Jacobs, W. R., Jr. (2002) Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in *Mycobacterium tuberculosis*, *M. bovis* BCG and *M. smegmatis*. *Microbiology* **148**, 3007–3017 [CrossRef Medline](#)
41. van Kessel, J. C., and Hatfull, G. F. (2007) Recombineering in *Mycobacterium tuberculosis*. *Nat. Methods* **4**, 147–152 [CrossRef Medline](#)
42. Stover, C. K., de la Cruz, V. F., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., and Hatfull, G. F. (1991) New use of BCG for recombinant vaccines. *Nature* **351**, 456–460 [CrossRef Medline](#)
43. Daffe, M., Brennan, P. J., and McNeil, M. (1990) Predominant structural features of the cell wall arabinogalactan of *Mycobacterium tuberculosis* as revealed through characterization of oligoglycosyl alditol fragments by gas chromatography/mass spectrometry and by  $^1\text{H}$  and  $^{13}\text{C}$  NMR analyses. *J. Biol. Chem.* **265**, 6734–6743 [Medline](#)
44. Wilmarth, P. A., Riviere, M. A., and David, L. L. (2009) Techniques for accurate protein identification in shotgun proteomic studies of human, mouse, bovine, and chicken lenses. *J. Ocul. Biol. Dis. Infor.* **2**, 223–234 [CrossRef Medline](#)
45. Otwinowski, Z., and Minor, W. (1997) [20] Processing of X-ray diffraction data collected in oscillation mode. *Methods in Enzymol.* **276**, 307–326 [CrossRef Medline](#)
46. Schneider, T. R., and Sheldrick G. M. (2002) Substructure solution with SHELXD. *Acta Crystallogr D Biol Crystallogr.* **58**, 1772–1779 [CrossRef Medline](#)
47. Pape, T., and Schneider, T. R. (2004) HKL2MAP: a graphical user interface for macromolecular phasing with SHELX programs. *J Appl Cryst.* **37**, 843–844 [CrossRef](#)
48. Terwilliger, T. C., Adams, P. D., Read, R. J., McCoy, A. J., Moriarty, N. W., Grosse-Kunstleve, R. W., Afonine, P. V., Zwart, P. H., and Hung, L. W. (2009) Decision-making in structure solution using Bayesian estimates of map quality: the PHENIX AutoSol wizard. *Acta Crystallogr D Biol Crystallogr.* **65**, 582–601 [CrossRef Medline](#)
49. Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., and Terwilliger, T. C. (2002) PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr.* **58**, 1948–1954 [CrossRef Medline](#)
50. Cowtan K. (2010) Recent developments in classical density modification. *Acta Crystallogr D Biol Crystallogr.* **66**, 470–478 [CrossRef Medline](#)
51. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr.* **60**, 2126–2132 [CrossRef Medline](#)
52. Howard, N. C., Marin, N. D., Ahmed, M., Rosa, B. A., Martin, J., Bambouskova, M., Sergushichev, A., Loginicheva, E., Kurepina, N., Rangel-Moreno, J., Chen, L., Kreiswirth, B. N., Klein, R. S., Balada-Llasat, J. M., Torrelles, J. B., et al. (2018) Mycobacterium tuberculosis carrying a rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid changes. *Nat. Microbiol.* **3**, 1099–1108 [CrossRef Medline](#)

**Structural and functional evidence that lipoprotein LpqN supports cell envelope biogenesis in *Mycobacterium tuberculosis***

Geoff C. Melly, Haley Stokas, Jennifer L. Dunaj, Fong Fu Hsu, Malligarjunan Rajavel, Chih-Chia Su, Edward W. Yu and Georgiana E. Purdy

*J. Biol. Chem.* 2019, 294:15711-15723.

doi: 10.1074/jbc.RA119.008781 originally published online August 30, 2019

---

Access the most updated version of this article at doi: [10.1074/jbc.RA119.008781](https://doi.org/10.1074/jbc.RA119.008781)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 51 references, 14 of which can be accessed free at <http://www.jbc.org/content/294/43/15711.full.html#ref-list-1>